Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Plasma Cell Disorders

Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution

Bone Marrow Transplantation volume 50, pages 658–662 (2015)Cite this article

Subjects

Abstract

The role of allogeneic hematopoietic SCT (allo-HCT) in multiple myeloma (MM) remains controversial. A total of 58 patients received an allo-HCT (25 of them with myeloablative conditioning—allo-MAC—and 33 with reduced-intensity conditioning—allo-RIC) at our institution over a 28-year period. The CR rate for allo-MAC was 36%. The incidence of grade III–IV acute GVHD (aGVHD) and chronic GVHD (cGVHD) was 28% and 39%, respectively The TRM at any time was 60% and the main causes of death were aGVHD or infectious complications not directly related to GVHD. The estimated PFS and OS at 15 years were 8% and 15%, respectively. The CR rate with allo-RIC was 45%. The incidence of grade III–IV aGVHD and cGVHD were 24% and 41%, respectively. The TRM at any time was 33% and was mainly related to aGVHD. The estimated PFS and OS at 5 years were 22% and 38%, respectively. Despite its high TRM, a proportion of patients with high-risk myeloma (early relapse and newly diagnosed ultrahigh risk) may obtain long-term disease control with allo-HCT. New approaches aimed at decreasing the incidence of aGVHD, and consequently to decrease the TRM, are needed.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Ludwig H, Bolejack V, Crowley J, Bladé J, San Miguel J, Kyle RA et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 2010; 28: 1599–05.

    Article  PubMed  Google Scholar 

  2. Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999; 17: 208–215.

    Article  CAS  PubMed  Google Scholar 

  3. Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003; 102: 1927–1929.

    Article  CAS  PubMed  Google Scholar 

  4. Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995; 13: 1312–1322.

    Article  CAS  PubMed  Google Scholar 

  5. Bensinger WI, Bucker CD, Anasetti C, Clift R, Storb R, Barnett T et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on oucome. Blood 1996; 88: 2787–2793.

    CAS  PubMed  Google Scholar 

  6. Gahrton G, Stevenson H, Cavo M, Apperley J, Bacigalupo A, Björkstrand B et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centre. Br J Haematol 2001; 113: 209–216.

    Article  CAS  PubMed  Google Scholar 

  7. Lokhorst H, Einsele H, Vesole D, Bruno B, San Miguel J, Pérez-Simón JA et al. International Myeloma Working Group consensus statement regarding the current status of allogeneic stem-cell transplantation for multiple myeloma. J Clin Oncol 2010; 28: 4521–4530.

    Article  PubMed  Google Scholar 

  8. Gahrton G, Iacobelli S, Björkstrand B, Hegnbart U, Gruber A, Greinix H et al. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study. Blood 2013; 121: 5055–5063.

    Article  CAS  PubMed  Google Scholar 

  9. Bladé J, Rosiñol L, Cibeira MT, Rovira M, Carreras E . Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655–3663.

    Article  PubMed  Google Scholar 

  10. Chng WJ, Dispenzieri A, Chim C-S, Fonseca R, Goldschmidt H, Lentzsch S et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia 2014; 28: 269–277.

    Article  CAS  PubMed  Google Scholar 

  11. Moreau P, Cavo M, Sonneveld P, Rosiñol L, Attal M, Pezzi A et al. The combination of ISS 3, high LDH and t(4;14) and/or del (17p) identify a simple prognostic index for overall survival in patients treated with novel agents-based induction therapy and front-line autologous stem cell transplantation and allow the definition of a subgroup of patients at high-risk of early death from progressive disease. J Clin Oncol 2014; 32: 2173–2180.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Durie BG, Harousseau JL, San Miguel J, Bladé J, Barlogie B, Anderson K et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.

    Article  CAS  PubMed  Google Scholar 

  13. Kaplan EL, Meier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  14. Peto R, Pike MC . Conservation of the approximation sigma (O-E)2-E in the log-rank test for survival data or tumor incidence data. Biometrics 1971; 29: 579–584.

    Article  Google Scholar 

  15. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591–3593.

    Article  PubMed  Google Scholar 

  16. Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L et al. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients. Br J Haematol 2013; 163: 474–482.

    Article  Google Scholar 

  17. Gahrton G . Progress in allogeneic transplantation for multiple myeloma. Eur J Haematol 2010; 85: 279–289.

    Article  CAS  PubMed  Google Scholar 

  18. Crawley C, Iacobelly S, BJörkstrand B, Apperley JF, Niederwieser D, Gahrton G . Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rated compared with myeloablative conditioning. Blood 2007; 109: 3588–3594.

    Article  CAS  PubMed  Google Scholar 

  19. Gahrton G, Iacobelly S, Bandini G, Björkstrand B, Corradini P, Crawley C et al. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma. Haematologica 2007; 92: 1513–1518.

    Article  PubMed  Google Scholar 

  20. Lokhorst HM, Segeren CM, Verdonck LF, van der Holt B, Raymakers R, van Oers MHJ et al. Partially T-cell depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol 2003; 21: 1728–1733.

    Article  PubMed  Google Scholar 

  21. Rotta M, Storer BE, Sahebi F, Shizuru JA, Bruno B, Lange T et al. Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. Blood 2009; 113: 3383–3391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Bruno B, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F et al. Nonmyeloablative allografing for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. Blood 2009; 113: 3375–3382.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. El-Cheikh J, Crocchhiolo R, Furst S, Stoppa AM, Ladaique P, Faucher C et al. Long-term outcome after allogeneic stem-cell transplantation with reduced-intensity conditioning in patients with multiple myeloma. Am J Hematol 2013; 88: 370–374.

    Article  CAS  PubMed  Google Scholar 

  24. Bensinger W, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P et al. Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. Bone Marrow Transplant 2012; 47: 1312–1317.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a g analysis. Blood 2011; 118: 1979–1988.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Gratwohl A . The EBMT risk score. Bone Marrow Transplant 2012; 47: 749–756.

    Article  CAS  PubMed  Google Scholar 

  27. Holtan SG, Pasquini M, Weisdorf DJ . Acute GvHD: a bench to bedside update. Blood 2014; 124: 363–367.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012; 18: 1859–1866.

    Article  PubMed  Google Scholar 

  29. Fuchs EJ . Haploidentical transplantation for hematologic malignancies: where do we stand? Hematology 2012; 2012: 230–236.

    PubMed  Google Scholar 

  30. Kröger N, Einsele H, Derigs G, Wandt H, Krüll A, Zander A . Long-term follow-up of an intensified myeloablative conditioning regimen with in vivo T cell depletion followed by allografting in patients with advanced multiple myeloma. Biol Blood Marrow Transplant 2010; 16: 861–864.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

This work has been supported in part by grants from the Instituto de Salud Carlos III, Spanish Ministry of Health (FIS PI12/01093 and RD12/0036/0046, National Plan I+D+I supported by Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional FEDER).

Author information

Authors and Affiliations

  1. Hematology Department, Hospital Clínic, IDIBAPS, Barcelona, Spain

    L Rosiñol, R Jiménez, M Rovira, C Martínez, F Fernández-Avilés, M Suárez-Lledó, G Gutiérrez-García, C Fernández de Larrea, E Carreras, A Urbano-Ispizua & J Bladé

  2. Bone Marrow Transplant Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain

    L Rosiñol, M Rovira, C Martínez, F Fernández-Avilés, P Marín, M Suárez-Lledó, G Gutiérrez-García, E Carreras & A Urbano-Ispizua

  3. Amyloid and Myeloma Unit, Hospital Clínic, IDIBAPS, Barcelona, Spain

    L Rosiñol, R Jiménez, C Fernández de Larrea & J Bladé

  4. Hemostherapy and Hemostasis Department, Hospital Clínic, IDIBAPS, Barcelona, Spain

    P Marín

  5. Institut of Research Josep Carreras, Barcelona, Spain

    A Urbano-Ispizua

Authors
  1. L Rosiñol
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Rovira
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Fernández-Avilés
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Marín
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M Suárez-Lledó
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G Gutiérrez-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Fernández de Larrea
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E Carreras
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. A Urbano-Ispizua
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Bladé
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Rosiñol.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosiñol, L., Jiménez, R., Rovira, M. et al. Allogeneic hematopoietic SCT in multiple myeloma: long-term results from a single institution. Bone Marrow Transplant 50, 658–662 (2015). https://doi.org/10.1038/bmt.2014.320

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.320

This article is cited by

Search

Advanced search

Quick links